How proven is a ‘proven intervention’? Ethics of placebo controls in light of conditional approval programs

Author:

Hug Kristina1ORCID

Affiliation:

1. Department of Clinical Sciences, Medical Ethics, BMC I12, Lund, 22184, Sweden

Abstract

This article discusses the difficulties of establishing whether there exists a proven therapeutic intervention when regenerative experimental treatments are made accessible to patients under conditional approval programs (outside clinical trials). Conditional approvals are often made on the basis of less robust efficacy evidence than otherwise required for the registration of new treatments. Lower quality of evidence affects the ethical justification of using a placebo-control design. The absence of a proven intervention is important in evaluating whether it is ethically justifiable to use such a design in a clinical trial and is present in major ethical guidelines. The main argument in this paper is that conditionally approved therapies, if referred to as ‘proven interventions’, would make placebo-control design ethically unjustifiable. Conducting rigorous clinical trials after conditional approvals is crucial to establish the efficacy of therapeutic approaches under such approvals. Hindrances to running such trials and generating further efficacy evidence are brought to attention.

Funder

European Union's Horizon 2020 research and innovation programme

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Reference55 articles.

1. FDA Regulation of Prescription Drugs

2. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects Council for International Organizations of Medical Sciences (CIOMS), Geneva, Switzerland, 1–119 (2002). https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf (Accessed 10 April 2021).

3. Update on unethical use of placebos in randomised trials

4. International Society for Stem Cell Research. ISSCR guidelines for the clinical translation of stem cells. (2008). (Accessed 10 April 2021) www.isscr.org/docs/default-source/clin-trans-guidelines/isscrglclinicaltrans.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3